Introduction {#sec1_1}
============

Hydroxychloroquine (Plaquenil) is a chloroquine derivative used in the treatment of many diseases including malaria, rheumatoid arthritis, and systemic lupus erythematosus. Retinal toxicity from hydroxychloroquine is rare, but even if the medication is discontinued, vision loss may be irreversible and may continue to progress. Before treatment is initiated, a complete ophthalmic examination should be performed to determine any baseline maculopathy. In early toxicity, there are no visible signs, but field, optical coherence tomography (OCT), and multifocal electroretinography (mfERG) changes can be detected \[[@B1]\].

Method {#sec1_2}
======

We report the case of a 53-year-old Caucasian female with a history of rheumatoid arthritis treated with hydroxychloroquine 400 mg daily for 9 years, between 2002 and 2011, who presented with distortion and decrease in vision, colour vision disturbances, and major central vision distortion for the last 2 months before presentation in June 2014.

Results {#sec1_3}
=======

Examination of this patient showed a best corrected visual acuity of 0.3 logMAR in both eyes, the Ishihara test revealed red/green colour vision unspecific disturbances, and her fundus examination revealed subtle pigment disturbances in both foveae but otherwise normal looking retina. OCT (fig. [1](#F1){ref-type="fig"}) revealed subfoveal changes in the outer retina and the retinal pigment epithelium layer. No visual field or electrophysiology testing was performed; however, a visual field test performed by her optician was normal except for few central changes. Fundus autofluorescence (FAF) revealed foveal pigment disturbances and an area of hypoautofluorescence outside the arcade that is symmetrical between the 2 eyes (fig. [2](#F2){ref-type="fig"}, fig. [3](#F3){ref-type="fig"}).

Discussion {#sec1_4}
==========

Hydroxychloroquine ocular toxicity includes keratopathy, ciliary body involvement, lens opacities, and retinopathy. The incidence of true hydroxychloroquine retinopathy is very low; although its pathogenesis is unclear, risk factors include daily dosage of hydroxychloroquine, cumulative dosage, duration of treatment, coexisting renal or liver disease, patient age, and concomitant retinal disease \[[@B2]\]. Patients usually complain of difficulty with reading, decreased vision, missing central vision, glare, blurred vision, light flashes, and metamorphopsia. They can also be asymptomatic.

Melles and Marmor \[[@B3]\] found that the overall prevalence of hydroxychloroquine retinopathy is 7.5% but varied with daily consumption \[odds ratio, 5.67; 95% confidence interval (CI), 4.14--7.79 for \>5.0 mg/kg\] and with duration of use (odds ratio, 3.22; 95% CI, 2.20--4.70 for \>10 years). For a daily consumption of 4.0--5.0 mg/kg, the prevalence of retinal toxicity remained less than 2% within the first 10 years of use but rose to almost 20% after 20 years of use. Other major risk factors include kidney disease (odds ratio, 2.08; 95% CI, 1.44--3.01) and concurrent tamoxifen citrate therapy (odds ratio, 4.59; 95% CI, 2.05--10.27) \[[@B3]\].

Greenstein et al. \[[@B4]\] evaluated patients with standard automated perimetry using the 10-2 and/or 24-2 visual field program (Zeiss, Meditec), mfERG, spectral-domain OCT (SD-OCT), and short-wavelength FAF. Their findings showed that 44% (15 patients) had abnormal results on at least 1 test; however, only 3% (2 patients) had abnormal results on all 4 tests. Excluding short-wavelength FAF, 7 of the 15 patients had abnormal visual fields, mfERG ring ratios, and SD-OCTs. The remaining 8 had abnormal mfERGs and/or visual fields and normal SD-OCTs. The authors found no evidence of abnormal SD-OCTs in the presence of normal mfERG and visual field results. They suggest that functional deficits precede structural changes seen on SD-OCT in these patients \[[@B4]\].

In early stages, mild changes are limited to a pericentral ring of increased FAF. More advanced stages present as pericentral mottled loss of FAF with increased FAF in the adjacent retina and later on a complete loss of pericentral FAF \[[@B5]\].

Lee et al. \[[@B6]\] found that a pericentral pattern of hydroxychloroquine retinopathy was predominant among Korean patients, rather than the traditional (bull\'s eye) parafoveal pattern of damage, in 8 out of 9 patients diagnosed with toxicity, among 218 patients screened.

The use of mfERG may detect retinal dysfunction in a considerable number of eyes with normal ophthalmoscopy and fluorescein angiography. The higher variability of colour vision and visual field testing results suggests the use of mfERG as a primary screening tool for retinal dysfunction in long-term hydroxychloroquine treatment \[[@B7]\].

In our case, the retinal changes only seen on FAF were very subtle in the foveal and macular area and were mainly in the area outside the arcades, mainly inferiorly, and very symmetrical, and occurred 3 years after cessation of the drug taken at a normal dose, however, for 9 years.

Due to normal fundus appearance apart from foveal changes, the lack of electrodiagnostic testing in our unit, and the patient not being keen on travelling to large centres for testing, we have not requested an ERG or simply an mfERG, which is the main weakness in our case report.

Although we cannot rule out the diagnosis of sectorial retinitis pigmentosa, the normal fundus appearance, normal visual field, absence of night vision problems, and lack of family history are all important factors against such a diagnosis. ERG testing would not show any changes as the area involved is not large enough to reduce the ERG waves. To the best of our knowledge, this aspect has never been reported before, especially in the Caucasian population, and the findings were not confined to the macular area.
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